Teacher Retirement System of Texas acquired a new position in shares of Glaukos Corp (NYSE:GKOS) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 6,309 shares of the medical instruments supplier’s stock, valued at approximately $256,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Amalgamated Bank purchased a new position in Glaukos during the second quarter worth $205,000. AdvisorNet Financial Inc boosted its stake in Glaukos by 470.4% during the first quarter. AdvisorNet Financial Inc now owns 5,362 shares of the medical instruments supplier’s stock worth $165,000 after buying an additional 4,422 shares during the period. Xact Kapitalforvaltning AB purchased a new position in Glaukos during the second quarter worth $248,000. First Republic Investment Management Inc. purchased a new position in Glaukos during the first quarter worth $268,000. Finally, Hartford Investment Management Co. purchased a new position in Glaukos during the second quarter worth $561,000.

In other news, COO Chris M. Calcaterra sold 8,771 shares of the business’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of $44.01, for a total transaction of $386,011.71. Following the completion of the sale, the chief operating officer now directly owns 248,771 shares of the company’s stock, valued at $10,948,411.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas William Burns sold 150,000 shares of the business’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $38.78, for a total transaction of $5,817,000.00. The disclosure for this sale can be found here. Insiders have sold 708,273 shares of company stock valued at $38,638,566 over the last three months. Insiders own 11.60% of the company’s stock.

Several research analysts have commented on the stock. BMO Capital Markets lifted their price objective on shares of Glaukos from $59.00 to $68.00 and gave the stock a “market perform” rating in a research note on Wednesday. Piper Jaffray Companies lifted their price objective on shares of Glaukos to $73.00 and gave the stock an “overweight” rating in a research note on Friday, August 31st. Berenberg Bank assumed coverage on shares of Glaukos in a research note on Thursday, August 30th. They set a “hold” rating and a $57.00 price objective for the company. Wells Fargo & Co lifted their price objective on shares of Glaukos from $50.00 to $74.00 and gave the stock an “outperform” rating in a research note on Thursday, August 30th. Finally, ValuEngine raised shares of Glaukos from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 29th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $56.90.

Shares of GKOS opened at $61.51 on Friday. The firm has a market cap of $2.20 billion, a PE ratio of 1,261.80 and a beta of 1.46. Glaukos Corp has a 12-month low of $23.08 and a 12-month high of $70.91.

Glaukos (NYSE:GKOS) last issued its earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). The company had revenue of $43.16 million for the quarter, compared to analysts’ expectations of $40.51 million. Glaukos had a negative net margin of 3.49% and a negative return on equity of 4.11%. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.10) earnings per share. sell-side analysts predict that Glaukos Corp will post -0.55 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Recommended Story: What are the Different Types of Leveraged Buyouts?

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.